• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Tozasertib

Tozasertib

Product ID T5996
Cas No. 639089-54-6
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $60.00 In stock
25 mg $105.00 In stock
100 mg $376.00 In stock
250 mg $721.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Tozasertib is an anticancer chemotherapeutic pan-aurora kinase (AurK) inhibitor that also inhibits FMS-like tyrosine kinase 3 (FLT3) and Abl. Tozasertib is currently in clinical trials as a potential treatment for acute lymphoblastic leukemia (ALL). In cellular models of cancer, tozasertib activates caspase-3 and PARP and decreases expression of HDAC, increasing apoptosis and inhibiting cell growth. In other cellular models, tozasertib inhibits cell proliferation and metastasis by blocking downstream ERK signaling and downregulating cdc25c and cyclin B. This compound also decreases tumor growth in an in vivo model of prostate cancer.

Product Info

Cas No.

639089-54-6

Purity

≥98%

Formula

C23H28N8OS

Formula Wt.

464.59

Chemical Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide

IUPAC Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide

Synonym

VX680, MK0457

Melting Point

245-260°C

Solubility

DMSO at 100 mg/mL

Appearance

White to pale yellow powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

T5996 MSDS PDF

Info Sheet

T5996 Info Sheet PDF

References

Okabe S, Tauchi T, Tanaka Y, et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 4;13(1):32. PMID: 23556431.

Li Y, Zhou W, Wei L, et al. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol. 2012 Dec;41(6):2139-49. PMID: 23007526.

Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. PMID: 22772060.

Jeet V, Russell PJ, Verma ND, et al. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets. 2012 Feb;12(2):144-63. PMID: 22229247.

Salah E, Ugochukwu E, Barr AJ, et al. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J Med Chem. 2011 Apr 14;54(7):2359-67. PMID: 21417343.

Oliveira TM, Ahmad R, Engh RA. VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. J Phys Chem A. 2011 Apr 28;115(16):3895-904. PMID: 21306143.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E4668

    ELR-510444

    Microtubule polymerization inhibitor.

    ≥98%
  • P7000

    PR-619

    Deubiquitinating enzyme inhibitor.

    ≥98%
  • C5970

    Corydaline

    Alkaloid compound found in Corydalis.

    ≥94%
  • W0275

    R-(+)-Warfarin Sodium >99%ee

    Coumarin; VKORC1 inhibitor.

    ≥99%
  • N1977

    Neurokinin A (4-10)

    Endogenous neuropeptide, also known as substanc...

    ≥95%
  • X4402

    XL-147

    Dual inhibitor of PI3K and mTOR.

    ≥98%
  • T0120

    2′,7-bis(triethylsilyl)taxol

    Synthesis intermediate

    ≥98%
  • S4244

    SKLB 610

    VEGFR2, PDGFR, FGFR2 inhibitor.

    ≥98%
  • G8101

    Guaifenesin

    Expectorant.

    ≥98%
  • N1978

    Neurokinin B

    Neuromodulator, biomarker

    ≥95%
  • O4402

    Olaparib

    PARP1/2 inhibitor.

    ≥98%
  • C0160

    Canrenone

    Metabolite of spironolactone; Na+/K+ ATPase par...

    ≥98%
  • A5272

    Angiotensin, dog/rat

    Peptide, derivative of AT I, cleavage product o...

    ≥95%
  • A7462

    Aspartame

    Dipeptide ester, commercial sweetener.

    ≥98%
  • A3208

    AICAR

    AMPK activator.

    ≥98%
  • T0004

    T2 toxin Triol

    Trichothecene mycotoxin produced by Fusarium; p...

    ≥97%, TLC
  • O9334

    Oxibendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥98%
  • N1986

    Neuropeptide Y, human/rat

    Endogenous peptide neurotransmitter, involved i...

    ≥95%
  • D3215

    Didymin

    Flavonoid glycoside found in citrus fruit.

    ≥98%
  • G4482

    Glucagon-like Peptide I (7-37)

    Endogenous peptide hormone, GLP-1 fragment, inv...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only